25 results on '"Pacheco-Herrero, Mar"'
Search Results
2. BACE1 and SCD1 are associated with neurodegeneration.
- Author
-
Bedoya-Guzmán, Ferley A., Pacheco-Herrero, Mar, Salomon-Cruz, Ivan Daniel, Barrera-Sandoval, Angela Maria, Gutierrez Vargas, Johanna Andrea, Villamil-Ortiz, Javier Gustavo, Lanau, Carlos Andres Villegas, David Arias-Londoño, Julián, Area-Gomez, Estela, and Cardona Gomez, Gloria Patricia
- Subjects
LIPID analysis ,COGNITION disorders ,CADASIL syndrome ,ENDOTHELIAL cells ,IN vitro studies ,KRUSKAL-Wallis Test ,STATISTICS ,RESEARCH ,BIOLOGICAL models ,ALZHEIMER'S disease ,MONOUNSATURATED fatty acids ,HIPPOCAMPUS (Brain) ,IN vivo studies ,ANALYSIS of variance ,CONFIDENCE intervals ,ANIMAL experimentation ,MICROSCOPY ,INFLAMMATION ,WESTERN immunoblotting ,IMMUNOHISTOCHEMISTRY ,ONE-way analysis of variance ,MULTIVARIATE analysis ,PROTEIN precursors ,PRECIPITIN tests ,RATS ,T-test (Statistics) ,COMPARATIVE studies ,RESEARCH funding ,DEMENTIA ,MASS spectrometry ,FLUORESCENT antibody technique ,DESCRIPTIVE statistics ,FACTOR analysis ,OXIDOREDUCTASES ,PHOSPHOLIPIDS ,DATA analysis ,STATISTICAL correlation ,NEURODEGENERATION ,CEREBRAL ischemia - Abstract
Introduction: Proteolytic processing of amyloid protein precursor by b-site secretase enzyme (BACE1) is dependent on the cellular lipid composition and is affected by endomembrane trafficking in dementia and Alzheimer's disease (AD). Stearoyl-CoA desaturase 1 (SCD1) is responsible for the synthesis of fatty acid monounsaturation (MUFAs), whose accumulation is strongly associated with cognitive dysfunction. Methods: In this study, we analyzed the relationship between BACE1 and SCD1 in vivo and in vitro neurodegenerative models and their association in familial AD (FAD), sporadic AD (SAD), and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using microscopy, biochemical, and mass SPECT approach. Results: Our findings showed that BACE1 and SCD1 immunoreactivities were increased and colocalized in astrocytes of the hippocampus in a rat model of global cerebral ischemia (2-VO). A synergistic effect of double BACE1/SCD1 silencing on the recovery of motor and cognitive functions was obtained. This neuroprotective regulation involved the segregation of phospholipids (PLs) associated with polyunsaturated fatty acids in the hippocampus, cerebrospinal fluid, and serum. The double silencing in the sham and ischemic groups was stronger in the serum, inducing an inverse ratio between total phosphatydilcholine (PC) and lysophosphatidylcholine (LPC), representedmainly by the reduction of PC 38:4 and PC 36:4 and an increase in LPC 16:0 and LPC 18:0. Furthermore, PC 38:4 and PC:36:4 levels augmented in pathological conditions in in vitro AD models. BACE1 and SCD1 increases were confirmed in the hippocampus of FAD, SAD, and CADASIL. Conclusion: Therefore, the findings suggest a novel convergence of BACE-1 and SCD1 in neurodegeneration, related to pro-inflammatory phospholipids. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Alzheimer's Disease: An Updated Overview of Its Genetics.
- Author
-
Andrade-Guerrero, Jesús, Santiago-Balmaseda, Alberto, Jeronimo-Aguilar, Paola, Vargas-Rodríguez, Isaac, Cadena-Suárez, Ana Ruth, Sánchez-Garibay, Carlos, Pozo-Molina, Glustein, Méndez-Catalá, Claudia Fabiola, Cardenas-Aguayo, Maria-del-Carmen, Diaz-Cintra, Sofía, Pacheco-Herrero, Mar, Luna-Muñoz, José, and Soto-Rojas, Luis O.
- Subjects
ALZHEIMER'S disease ,GENETICS ,AMYLOID beta-protein precursor ,TAU proteins ,GENETIC variation ,GENETIC mutation - Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disease in the world. It is classified as familial and sporadic. The dominant familial or autosomal presentation represents 1–5% of the total number of cases. It is categorized as early onset (EOAD; <65 years of age) and presents genetic mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), or the Amyloid precursor protein (APP). Sporadic AD represents 95% of the cases and is categorized as late-onset (LOAD), occurring in patients older than 65 years of age. Several risk factors have been identified in sporadic AD; aging is the main one. Nonetheless, multiple genes have been associated with the different neuropathological events involved in LOAD, such as the pathological processing of Amyloid beta (Aβ) peptide and Tau protein, as well as synaptic and mitochondrial dysfunctions, neurovascular alterations, oxidative stress, and neuroinflammation, among others. Interestingly, using genome-wide association study (GWAS) technology, many polymorphisms associated with LOAD have been identified. This review aims to analyze the new genetic findings that are closely related to the pathophysiology of AD. Likewise, it analyzes the multiple mutations identified to date through GWAS that are associated with a high or low risk of developing this neurodegeneration. Understanding genetic variability will allow for the identification of early biomarkers and opportune therapeutic targets for AD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Oxidative Stress and Mitochondrial Complex I Dysfunction Correlate with Neurodegeneration in an α-Synucleinopathy Animal Model.
- Author
-
Morales-Martínez, Adriana, Martínez-Gómez, Paola A., Martinez-Fong, Daniel, Villegas-Rojas, Marcos M., Pérez-Severiano, Francisca, Del Toro-Colín, Miguel A., Delgado-Minjares, Karen M., Blanco-Alvarez, Víctor Manuel, Leon-Chavez, Bertha Alicia, Aparicio-Trejo, Omar Emiliano, Baéz-Cortés, Mauricio T., Cardenas-Aguayo, Maria-del-Carmen, Luna-Muñoz, José, Pacheco-Herrero, Mar, Angeles-López, Quetzalli D., Martínez-Dávila, Irma A., Salinas-Lara, Citlaltepetl, Romero-López, José Pablo, Sánchez-Garibay, Carlos, and Méndez-Cruz, Adolfo R.
- Subjects
OXIDATIVE stress ,PEROXISOME proliferator-activated receptors ,PARKINSON'S disease ,NEURODEGENERATION ,MITOCHONDRIA ,SCRAPIE - Abstract
The α-synucleinopathies constitute a subset of neurodegenerative disorders, of which Parkinson's disease (PD) is the most common worldwide, characterized by the accumulation of misfolded α-synuclein in the cytoplasm of neurons, which spreads in a prion-like manner to anatomically interconnected brain areas. However, it is not clear how α-synucleinopathy triggers neurodegeneration. We recently developed a rat model through a single intranigral administration of the neurotoxic β-sitosterol β-D-glucoside (BSSG), which produces α-synucleinopathy. In this model, we aimed to evaluate the temporal pattern of levels in oxidative and nitrosative stress and mitochondrial complex I (CI) dysfunction and how these biochemical parameters are associated with neurodegeneration in different brain areas with α-synucleinopathy (Substantia nigra pars compacta, the striatum, in the hippocampus and the olfactory bulb, where α-syn aggregation spreads). Interestingly, an increase in oxidative stress and mitochondrial CI dysfunction accompanied neurodegeneration in those brain regions. Furthermore, in silico analysis suggests a high-affinity binding site for BSSG with peroxisome proliferator-activated receptors (PPAR) alpha (PPAR-α) and gamma (PPAR-γ). These findings will contribute to elucidating the pathophysiological mechanisms associated with α-synucleinopathies and lead to the identification of new early biomarkers and therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Autophagy: A Key Regulator of Homeostasis and Disease: An Overview of Molecular Mechanisms and Modulators.
- Author
-
Gómez-Virgilio, Laura, Silva-Lucero, Maria-del-Carmen, Flores-Morelos, Diego-Salvador, Gallardo-Nieto, Jazmin, Lopez-Toledo, Gustavo, Abarca-Fernandez, Arminda-Mercedes, Zacapala-Gómez, Ana-Elvira, Luna-Muñoz, José, Montiel-Sosa, Francisco, Soto-Rojas, Luis O., Pacheco-Herrero, Mar, and Cardenas-Aguayo, Maria-del-Carmen
- Subjects
AUTOPHAGY ,COVID-19 ,HOMEOSTASIS ,LYSOSOMES ,CEREBROVASCULAR disease ,CELL physiology ,NEURODEGENERATION ,COMMUNICABLE diseases - Abstract
Autophagy is a highly conserved lysosomal degradation pathway active at basal levels in all cells. However, under stress conditions, such as a lack of nutrients or trophic factors, it works as a survival mechanism that allows the generation of metabolic precursors for the proper functioning of the cells until the nutrients are available. Neurons, as post-mitotic cells, depend largely on autophagy to maintain cell homeostasis to get rid of damaged and/or old organelles and misfolded or aggregated proteins. Therefore, the dysfunction of this process contributes to the pathologies of many human diseases. Furthermore, autophagy is highly active during differentiation and development. In this review, we describe the current knowledge of the different pathways, molecular mechanisms, factors that induce it, and the regulation of mammalian autophagy. We also discuss its relevant role in development and disease. Finally, here we summarize several investigations demonstrating that autophagic abnormalities have been considered the underlying reasons for many human diseases, including liver disease, cardiovascular, cerebrovascular diseases, neurodegenerative diseases, neoplastic diseases, cancers, and, more recently, infectious diseases, such as SARS-CoV-2 caused COVID-19 disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Biomarker Candidates for Alzheimer's Disease Unraveled through In Silico Differential Gene Expression Analysis.
- Author
-
Silva-Lucero, Maria-del-Carmen, Rivera-Osorio, Jared, Gómez-Virgilio, Laura, Lopez-Toledo, Gustavo, Luna-Muñoz, José, Montiel-Sosa, Francisco, Soto-Rojas, Luis O., Pacheco-Herrero, Mar, and Cardenas-Aguayo, Maria-del-Carmen
- Subjects
ALZHEIMER'S disease ,GENE expression ,BIOMARKERS ,CELL anatomy ,FUNCTIONAL analysis - Abstract
Alzheimer's disease (AD) is neurodegeneration that accounts for 60–70% of dementia cases. Symptoms begin with mild memory difficulties and evolve towards cognitive impairment. The underlying risk factors remain primarily unclear for this heterogeneous disorder. Bioinformatics is a relevant research tool that allows for identifying several pathways related to AD. Open-access databases of RNA microarrays from the peripheral blood and brain of AD patients were analyzed after background correction and data normalization; the Limma package was used for differential expression analysis (DEA) through statistical R programming language. Data were corrected with the Benjamini and Hochberg approach, and genes with p-values equal to or less than 0.05 were considered to be significant. The direction of the change in gene expression was determined by its variation in the log2-fold change between healthy controls and patients. We performed the functional enrichment analysis of GO using goana and topGO-Limma. The functional enrichment analysis of DEGs showed upregulated (UR) pathways: behavior, nervous systems process, postsynapses, enzyme binding; downregulated (DR) were cellular component organization, RNA metabolic process, and signal transduction. Lastly, the intersection of DEGs in the three databases showed eight shared genes between brain and blood, with potential use as AD biomarkers for blood tests. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Rapid β-Amyloid Deposition and Cognitive Impairment After Cholinergic Denervation in APP/PS1 Mice
- Author
-
Ramos-Rodriguez, Juan Jose, Pacheco-Herrero, Mar, Thyssen, Diana, Murillo-Carretero, Maria Isabel, Berrocoso, Esther, Spires-Jones, Tara L., Bacskai, Brian J., and Garcia-Alloza, Monica
- Published
- 2013
- Full Text
- View/download PDF
8. Hispano‐American Brain Bank on Neurodevelopmental Disorders: An initiative to promote brain banking, research, education, and outreach in the field of neurodevelopmental disorders.
- Author
-
Dufour, Brett D., Albores‐Gallo, Lilia, Luna‐Muñoz, Jose, Hagerman, Randi, Miquelajauregui, Amaya, Buriticá, Efrain, Saldarriaga, Wilmar, Pacheco‐Herrero, Mar, Yris Silvestre‐Sosa, Ana, Mazefsky, Carla, Gastgeb, Holly, Kofler, Julia, Casanova, Manuel, Hof, Patrick R., London, Eric, Hagerman, Paul, and Martínez‐Cerdeño, Verónica
- Subjects
BRAIN banks ,FRAGILE X syndrome ,NEURAL development ,AUTISM spectrum disorders ,CULTURAL pluralism - Abstract
Neurodevelopmental disorders (NDDs) are conditions that present with brain dysfunction due to alterations in the processes of brain development. They present with neuropsychiatric, cognitive, and motor symptoms. Autism spectrum disorder (ASD) and Fragile X syndrome (FXS) are two of the most common NDDs. Human brain tissue is a scarce resource that is obtained from postmortem donations. In the case of NDDs, specifically autism, the reduced donation rate of brains prevents researchers to investigate its pathology and fine anatomy. The Hispano‐American Brain Bank of Neurodevelopmental Disorders (Banco Hispanoamericano de CErebros de trastornos del NEurodesarrollo) or CENE is a large‐scale brain bank for neurodevelopmental disorders in Hispano‐America and the US. CENE's objectives are to collect and distribute brains of patients with NDDS, with a focus on ASD and FXS, to perform research, promote education of future scientists, and enhance public awareness about the importance of human tissue availability for scientific research on brain function and disease. CENE has thus far established a bilingual system of nodes and teams in several American countries including California‐US, Pennsylvania‐US, México, Puerto Rico, Colombia, and Dominican Republic. CENE ensures that postmortem NDD samples used in research better match the world's genetic and ethnic diversity. CENE enables and expands NDD brain research worldwide, particularly with respect to ASD and FXS. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Current Status and Challenges of Stem Cell Treatment for Alzheimer's Disease.
- Author
-
Pacheco-Herrero, Mar, Soto-Rojas, Luis O., Reyes-Sabater, Heidy, Garcés-Ramirez, Linda, de la Cruz López, Fidel, Villanueva-Fierro, Ignacio, and Luna-Muñoz, José
- Subjects
- *
ALZHEIMER'S disease , *STEM cell treatment , *PROGRESSIVE supranuclear palsy , *TAU proteins , *AMYLOID plaque - Abstract
Neurodegenerative diseases called tauopathies, such as Alzheimer's disease (AD), frontotemporal dementia, progressive supranuclear palsy, and Parkinson's disease, among others, are characterized by the pathological processing and accumulation of tau protein. AD is the most prevalent neurodegenerative disease and is characterized by two lesions: neurofibrillary tangles (NFTs) and neuritic plaques. The presence of NFTs in the hippocampus and neocortex in early and advanced stages, respectively, correlates with the patient's cognitive deterioration. So far, no drugs can prevent, decrease, or limit neuronal death due to abnormal pathological tau accumulation. Among potential non-pharmacological treatments, physical exercise has been shown to stimulate the development of stem cells (SCs) and may be useful in early stages. However, this does not prevent neuronal death from the massive accumulation of NFTs. In recent years, SCs therapies have emerged as a promising tool to repopulate areas involved in cognition in neurodegenerative diseases. Unfortunately, protocols for SCs therapy are still being developed and the mechanism of action of such therapy remains unclear. In this review, we show the advances and limitations of SCs therapy. Finally, we provide a critical analysis of its clinical use for AD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Tau Protein Phosphorylated at Threonine-231 is Expressed Abundantly in the Cerebellum in Prion Encephalopathies.
- Author
-
Gómez-López, Vıctor Manuel, Viramontes-Pintos, Amparo, Ontiveros-Torres, Miguel Ángel, Garcés-Ramírez, Linda, de la Cruz, Fidel, Villanueva-Fierro, Ignacio, Bravo-Muñoz, Marely, Harrington, Charles R., Martínez-Robles, Sandra, Yescas, Petra, Guadarrama-Ortíz, Parménides, Hernandes-Alejandro, Mario, Montiel-Sosa, Francisco, Pacheco-Herrero, Mar, Luna-Muñoz, José, Manuel Gómez-López, Vıctor, and Hernándes-Alejandro, Mario
- Subjects
TAU proteins ,GLIAL fibrillary acidic protein ,PRIONS ,BOVINE spongiform encephalopathy ,MATRIX metalloproteinases ,CEREBRAL amyloid angiopathy ,PRION diseases ,RESEARCH ,NERVE tissue proteins ,BRAIN diseases ,CATTLE ,CREUTZFELDT-Jakob disease ,THREONINE ,ANIMAL experimentation ,RESEARCH methodology ,EVALUATION research ,CEREBELLUM ,COMPARATIVE studies - Abstract
Background: Transmissible spongiform encephalopathies (TSEs) are rare neurodegenerative disorders that affect animals and humans. Bovine spongiform encephalopathy (BSE) in cattle, and Creutzfeld-Jakob Disease (CJD) in humans belong to this group. The causative agent of TSEs is called "prion", which corresponds to a pathological form (PrPSc) of a normal cellular protein (PrPC) expressed in nerve cells. PrPSc is resistant to degradation and can induce abnormal folding of PrPC, and TSEs are characterized by extensive spongiosis and gliosis and the presence of PrPSc amyloid plaques. CJD presents initially with clinical symptoms similar to Alzheimer's disease (AD). In AD, tau aggregates and amyloid-β protein plaques are associated with memory loss and cognitive impairment in patients.Objective: In this work, we study the role of tau and its relationship with PrPSc plaques in CJD.Methods: Multiple immunostainings with specific antibodies were carried out and analyzed by confocal microscopy.Results: We found increased expression of the glial fibrillary acidic protein (GFAP) and matrix metalloproteinase (MMP-9), and an exacerbated apoptosis in the granular layer in cases with prion disease. In these cases, tau protein phosphorylated at Thr-231 was overexpressed in the axons and dendrites of Purkinje cells and the extensions of parallel fibers in the cerebellum.Conclusion: We conclude that phosphorylation of tau may be a response to a toxic and inflammatory environment generated by the pathological form of prion. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
11. Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection.
- Author
-
Pacheco-Herrero, Mar, Soto-Rojas, Luis O., Harrington, Charles R., Flores-Martinez, Yazmin M., Villegas-Rojas, Marcos M., León-Aguilar, Alfredo M., Martínez-Gómez, Paola A., Campa-Córdoba, B. Berenice, Apátiga-Pérez, Ricardo, Corniel-Taveras, Carolin N., Dominguez-García, Jesabelle de J., Blanco-Alvarez, Víctor Manuel, and Luna-Muñoz, José
- Subjects
COVID-19 ,SARS-CoV-2 ,NEUROLOGICAL disorders ,VIRUS diseases ,NEUROLOGIC manifestations of general diseases - Abstract
The current pandemic caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a public health emergency. To date, March 1, 2021, coronavirus disease 2019 (COVID-19) has caused about 114 million accumulated cases and 2.53 million deaths worldwide. Previous pieces of evidence suggest that SARS-CoV-2 may affect the central nervous system (CNS) and cause neurological symptoms in COVID-19 patients. It is also known that angiotensin-converting enzyme-2 (ACE2), the primary receptor for SARS-CoV-2 infection, is expressed in different brain areas and cell types. Thus, it is hypothesized that infection by this virus could generate or exacerbate neuropathological alterations. However, the molecular mechanisms that link COVID-19 disease and nerve damage are unclear. In this review, we describe the routes of SARS-CoV-2 invasion into the central nervous system. We also analyze the neuropathologic mechanisms underlying this viral infection, and their potential relationship with the neurological manifestations described in patients with COVID-19, and the appearance or exacerbation of some neurodegenerative diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration.
- Author
-
Martínez-Maldonado, Alejandra, Ángel Ontiveros-Torres, Miguel, Harrington, Charles R., Francisco Montiel-Sosa, José, García-Tapia Prandiz, Raúl, Bocanegra-López, Patricia, Sorsby-Vargas, Andrew Michael, Bravo-Muñoz, Marely, Florán-Garduño, Benjamín, Villanueva-Fierro, Ignacio, Perry, George, Garcés-Ramírez, Linda, de la Cruz, Fidel, Martínez-Robles, Sandra, Pacheco-Herrero, Mar, Luna-Muñoz, José, Ontiveros-Torres, Miguel Ángel, Montiel-Sosa, José Francisco, and Prandiz, Raúl García-Tapia
- Subjects
PROGRESSIVE supranuclear palsy ,TAU proteins ,NEUROFIBRILLARY tangles ,POST-translational modification ,NEUROGLIA ,ALZHEIMER'S disease - Abstract
Background: Alzheimer's disease (AD) and progressive supranuclear palsy (PSP) are examples of neurodegenerative diseases, characterized by abnormal tau inclusions, that are called tauopathies. AD is characterized by highly insoluble paired helical filaments (PHFs) composed of tau with abnormal post-translational modifications. PSP is a neurodegenerative disease with pathological and clinical heterogeneity. There are six tau isoforms expressed in the adult human brain, with repeated microtubule-binding domains of three (3R) or four (4R) repeats. In AD, the 4R:3R ratio is 1:1. In PSP, the 4R isoform predominates. The lesions in PSP brains contain phosphorylated tau aggregates in both neurons and glial cells.Objective: Our objective was to evaluate and compare the processing of pathological tau in PSP and AD.Methods: Double and triple immunofluorescent labeling with antibodies to specific post-translational tau modifications (phosphorylation, truncation, and conformational changes) and thiazin red (TR) staining were carried out and analyzed by confocal microscopy.Results: Our results showed that PSP was characterized by phosphorylated tau in neurofibrillary tangles (NFTs) and glial cells. Tau truncated at either Glu391 or Asp421 was not observed. Extracellular NFTs (eNFTs) and glial cells in PSP exhibited a strong affinity for TR in the absence of intact or phosphorylated tau.Conclusion: Phosphorylated tau was as abundant in PSP as in AD. The development of eNFTs from both glial cells and neuronal bodies suggests that truncated tau species, different from those observed in AD, could be present in PSP. Additional studies on truncated tau within PSP lesions could improve our understanding of the pathological processing of tau and help identify a discriminatory biomarker for AD and PSP. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. Human Dental Pulp Stem Cells Display a Potential for Modeling Alzheimer Disease-Related Tau Modifications.
- Author
-
Gazarian, Karlen, Ramirez-Garcia, Luis, Tapía Orozco, Luis, Luna-Muñoz, José, and Pacheco-Herrero, Mar
- Subjects
DENTAL pulp ,STEM cells ,NEUROFIBRILLARY tangles ,ALZHEIMER'S disease ,TEST systems - Abstract
We present here the first description of tau in human dental pulp stem cells (DPSCs) evidenced by RT-PCR data on expression of the gene MAPT and by immunocytochemical detection of epitopes by 12 anti-tau antibodies. The tau specificity of eight of these antibodies was confirmed by their affinity to neurofibrillary tangles (NFTs) in Alzheimer's disease (AD) postmortem brain samples. We therefore used DPSCs and AD brain samples as a test system for determining the probability of the involvement of tau epitopes in the mechanisms converting tau into NFT in AD. Three antibodies to non-phosphorylated and seven antibodies to phosphorylated epitopes bound tau in both DPSCs and AD NFTs, thus suggesting that their function was not influenced by inducers of formation of NFTs in the AD brain. In contrast, AT100, which recognizes a hyperphosphorylated epitope, did not detect it in the cytoplasm of DPSCs but detected it in AD brain NFTs, demonstrating its AD diagnostic potential. This indicated that the phosphorylation/conformational events required for the creation of this epitope do not occur in normal cytoplasm and are a part of the mechanism (s) leading to NFT in AD brain. TG3 bound tau in the cytoplasm and in mitotic chromosomes but did not find it in nuclei. Collectively, these observations characterize DPSCs as a novel tau-harboring neuronal lineage long-term propagable in vitro cellular system for the normal conformational state of tau sites, detectable by antibodies, with their state in AD NFTs revealing those involved in the pathological processes converting tau into NFTs in the course of AD. With this information, one can model the interaction of tau with inducers and inhibitors of hyperphosphorylation toward NFT-like aggregates to search for drug candidates. Additionally, the clonogenicity of DPSCs provides the option for generation of cell lineages with CRISPR-mutagenized genes of familial AD modeling. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer's Disease.
- Author
-
Luna-Viramontes, Nabil Itzi, Campa-Córdoba, B. Berenice, Ontiveros-Torres, Miguel Ángel, Harrington, Charles R., Villanueva-Fierro, Ignacio, Guadarrama-Ortíz, Parménides, Garcés-Ramírez, Linda, de la Cruz, Fidel, Hernandes-Alejandro, Mario, Martínez-Robles, Sandra, González-Ballesteros, Erik, Pacheco-Herrero, Mar, and Luna-Muñoz, José
- Subjects
ALZHEIMER'S disease ,TAU proteins ,COGNITION ,NEUROFIBRILLARY tangles ,PATHOLOGY - Abstract
Worldwide, around 50 million people have dementia. Alzheimer's disease (AD) is the most common type of dementia and one of the major causes of disability and dependency among the elderly worldwide. Clinically, AD is characterized by impaired memory accompanied by other deficiencies in the cognitive domain. Neuritic plaques (NPs) and neurofibrillary tangles (NFTs) are histopathological lesions that define brains with AD. NFTs consist of abundant intracellular paired helical filaments (PHFs) whose main constituent is tau protein. Tau undergoes posttranslational changes including hyperphosphorylation and truncation, both of which favor conformational changes in the protein. The sequential pathological processing of tau is illustrated with the following specific markers: pT231, TG3, AT8, AT100, and Alz50. Two proteolysis sites for tau have been described—truncation at glutamate 391 and at aspartate 421—and which can be demonstrated by reactivity with the antibodies 423 and TauC-3, respectively. In this review, we describe the molecular changes in tau protein as pre-NFTs progress to extracellular NFTs and during which the formation of a minimal nucleus of the filament, as the PHF core, occurs. We also analyzed the PHF core as the initiator of PHFs and tau phosphorylation as a protective neuronal mechanism against the assembly of the PHF core. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. National Dementia BioBank: A Strategy for the Diagnosis and Study of Neurodegenerative Diseases in México.
- Author
-
Reyes-Pablo, Aldelmo Emmanuel, Campa-Córdoba, B. Berenice, Luna-Viramontes, Nabil Itzi, Ontiveros-Torres, Miguel Ángel, Villanueva-Fierro, Ignacio, Bravo-Muñoz, Marely, Sáenz-Ibarra, Bárbara, Barbosa, Oralia, Guadarrama-Ortíz, Parménides, Garcés-Ramírez, Linda, de la Cruz, Fidel, Harrington, Charles R., Martínez-Robles, Sandra, González-Ballesteros, Erik, Perry, George, Pacheco-Herrero, Mar, Luna-Muñoz, José, and Moreira, Paula
- Subjects
NEURODEGENERATION ,ALZHEIMER'S disease ,DEMENTIA ,DIAGNOSIS ,TAU proteins - Abstract
We recently developed the National Dementia Biobank in México (BioBanco Nacional de Demencias, BND) as a unit for diagnosis, research, and tissue transfer for research purposes. BND is associated with the Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de Mexico (UNAM), Mexico. The donation of fluids, brain, and other organs of deceased donors is crucial for understanding the underlying mechanisms of neurodegenerative diseases and for the development of successful treatment. Our laboratory research focuses on 1) analysis of the molecular processing of the proteins involved in those neurodegenerative diseases termed tauopathies and 2) the search for biomarkers for the non-invasive and early diagnosis of Alzheimer's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimer's Disease.
- Author
-
Hernandes-Alejandro, Mario, Montaño, Sarita, Harrington, Charles R., Wischik, Claude M., Salas-Casas, Andrés, Cortes-Reynosa, Pedro, Pérez Salazar, Eduardo, Cazares-Apatiga, Javier, Apatiga-Perez, Ricardo, Ontiveros Torres, Miguel Ángel, Perry, George, Pacheco-Herrero, Mar, Luna-Muñoz, José, and Ávila, Jesús
- Subjects
TAU proteins ,ALZHEIMER'S disease ,POST-translational modification ,AMINO acid residues ,MOLECULAR dynamics - Abstract
Background: Neurofibrillary tangles (NFTs) and amyloid plaques are the neuropathological hallmarks in brains with Alzheimer's disease (AD). Post-translational modifications of tau, such as phosphorylation and truncation, have been proposed as initiators in the assembly of the abnormal paired helical filaments that constitute the NFTs. Neurons and NFTs are sites of matrix metalloproteinases (MMPs).Objective: The aim of this study was to analyze the relationship of MMP-9 and tau protein in brain samples with AD.Methods: This study was performed on brain tissue samples from patients with early, moderate, and late AD. MMPs and tau levels were analyzed by western blot and gelatin-substrate zymography. Immunofluorescence techniques and confocal microscopy were used to analyze the presence of both proteins in NFTs. Further, molecular dynamics simulations (MDS) and protein-protein docking were conducted to predict interaction between MMP-9 and tau protein.Results: MMP-9 expression was greatest in moderate and late AD, whereas MMP-2 expression was only increased in late-stage AD. Interestingly, confocal microscopy revealed NFTs in which there was co-localization of MMP-9 and tau protein. MDS and protein-protein docking predictions indicate that a high-affinity complex can be formed between MMP-9 and full-length tau protein.Conclusion: These observations provide preliminary evidence of an interaction between these two proteins. Post-translational modifications of tau protein, such as C-terminal truncation or phosphorylation of amino acid residues in the MMP-9 recognition site and conformational changes in the protein, such as folding of the N-terminal sequence over the three-repeat domain, could preclude the interaction between MMP-9 and tau protein during stages of NFT development. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. Increased Aβ production prompts the onset of glucose intolerance and insulin resistance.
- Author
-
Jiménez-Palomares, Margarita, Ramos-Rodríguez, Juan José, López-Acosta, José Francisco, Pacheco-Herrero, Mar, Lechuga-Sancho, Alfonso M., Perdomo, Germán, García-Alloza, Mónica, and Cózar-Castellano, Irene
- Abstract
Type 2 diabetes (T2D) mellitus and Alzheimer's disease (AD) are two prevalent diseases with comparable pathophysiological features and genetic predisposition. Patients with AD are more susceptible to develop T2D. However, the molecular mechanism linking AD and T2D remains elusive. In this study, we have generated a new mouse model to test the hypothesis that AD would prompt the onset of T2D in mice. To test our hypothesis, we crossed Alzheimer APPswe/PS1dE9 (APP/PS1) transgenic mice with mice partially deficient in leptin signaling (db/+). Body weight, plasma glucose, and insulin levels were monitored. Phenotypic characterization of glucose metabolism was performed using glucose and insulin tolerance tests. β-Cell mass, islet volume, and islet number were analyzed by histomorphometry. APP/ PS1 coexpression in mice with intact leptin receptor signaling did not show any metabolic perturbations in glucose metabolism or insulin sensitivity. In contrast, APP/PS1 coexpression in db/+ mice resulted in nonfasting hyperglycemia, hyperinsulinemia, and hypercholesterolemia without changes in body weight. Conversely, fasting blood glucose and cholesterol levels remained unchanged. Coinciding with altered glucose metabolism, APP/PS1 coexpression in db/+ mice resulted in glucose intolerance, insulin resistance, and impaired insulin signaling. In addition, histomorphometric analysis of pancreata revealed augmented β-cell mass. Taken together, these findings provide experimental evidence to support the notion that aberrant Aβ production might be a mechanistic link underlying the pathology of insulin resistance and T2D in AD. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Neurovascular unit dysfunction in Alzheimer's disease.
- Author
-
Soto‐Rojas, Luis Oskar, Pacheco‐Herrero, Mar, de la Cruz‐López, Fidel, Harrington, Charles R, Gevorkian, Goar, Garcés‐Ramírez, Linda, and Luna‐Muñoz, José
- Abstract
Background: Alzheimer's disease (AD) is the most common neurodegenerative disease worldwide. Histopathologically, AD presents with two hallmarks: neurofibrillary tangles (NFTs), and aggregates of amyloid β peptide (Aβ) both in the brain parenchyma as neuritic plaques, and around blood vessels as cerebral amyloid angiopathy. According to the vascular hypothesis of AD, vascular risk factors can result in dysregulation of the neurovascular unit (NVU) and hypoxia. Hypoxia may reduce Aβ clearance from the brain and increase its production, leading to both parenchymal and vascular accumulation of Aβ. An increase in Aβ amplifies neuronal dysfunction, NFT formation, and accelerates neurodegeneration, resulting in dementia. Our aim, we analyzed different Aβ species and their association with NVU. Method: We evaluated controls and AD human brains. Immunofluorescence assays were performed against different Aβ species and the main cellular and structural components of the NVU. Result: Our results evidenced that there are insoluble vascular deposits of both full‐length and truncated Aβ species. Furthermore, insoluble vascular Aβ aggregates are associated with a decrease phenotype of the cellular components that make up the NVU, as well as with the BBB disruption. Conclusion: This new insight into the pathological role of insoluble vascular Aβ could help to identify new therapeutic targets against key molecules and receptors in NVU, which may prevent or treat the insoluble Aβ vascular accumulation in AD brains. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Mechanistic Insight from Preclinical Models of Parkinson's Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy.
- Author
-
Delgado-Minjares, Karen M., Martinez-Fong, Daniel, Martínez-Dávila, Irma A., Bañuelos, Cecilia, Gutierrez-Castillo, M. E., Blanco-Alvarez, Víctor Manuel, Cardenas-Aguayo, Maria-del-Carmen, Luna-Muñoz, José, Pacheco-Herrero, Mar, and Soto-Rojas, Luis O.
- Subjects
PARKINSON'S disease ,CLINICAL trials ,ANIMAL models in research ,NEUROINFLAMMATION ,TREATMENT effectiveness ,DEEP brain stimulation - Abstract
Parkinson's disease (PD) is characterized by four pathognomonic hallmarks: (1) motor and non-motor deficits; (2) neuroinflammation and oxidative stress; (3) pathological aggregates of the α-synuclein (α-syn) protein; (4) neurodegeneration of the nigrostriatal system. Recent evidence sustains that the aggregation of pathological α-syn occurs in the early stages of the disease, becoming the first trigger of neuroinflammation and subsequent neurodegeneration. Thus, a therapeutic line aims at striking back α-synucleinopathy and neuroinflammation to impede neurodegeneration. Another therapeutic line is restoring the compromised dopaminergic system using neurotrophic factors, particularly the glial cell-derived neurotrophic factor (GDNF). Preclinical studies with GDNF have provided encouraging results but often lack evaluation of anti-α-syn and anti-inflammatory effects. In contrast, clinical trials have yielded imprecise results and have reported the emergence of severe side effects. Here, we analyze the discrepancy between preclinical and clinical outcomes, review the mechanisms of the aggregation of pathological α-syn, including neuroinflammation, and evaluate the neurorestorative properties of GDNF, emphasizing its anti-α-syn and anti-inflammatory effects in preclinical and clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer's Disease Brains.
- Author
-
Soto-Rojas, Luis O., Campa-Córdoba, B. Berenice, Harrington, Charles R., Salas-Casas, Andrés, Hernandes-Alejandro, Mario, Villanueva-Fierro, Ignacio, Bravo-Muñoz, Marely, Garcés-Ramírez, Linda, De La Cruz-López, Fidel, Ontiveros-Torres, Miguel Ángel, Gevorkian, Goar, Pacheco-Herrero, Mar, Luna-Muñoz, José, Rosenmann, Hanna, and Frenkel, Dan
- Subjects
ALZHEIMER'S disease ,BRAIN diseases ,BLOOD-brain barrier ,AMYLOID ,CELL anatomy ,NEURODEGENERATION - Abstract
Alzheimer's disease (AD) is a neurodegenerative disease, characterized histopathologically by intra-neuronal tau-related lesions and by the accumulation of amyloid β-peptide (Aβ) in the brain parenchyma and around cerebral blood vessels. According to the vascular hypothesis of AD, an alteration in the neurovascular unit (NVU) could lead to Aβ vascular accumulation and promote neuronal dysfunction, accelerating neurodegeneration and dementia. To date, the effects of insoluble vascular Aβ deposits on the NVU and the blood–brain barrier (BBB) are unknown. In this study, we analyze different Aβ species and their association with the cells that make up the NVU. We evaluated post-mortem AD brain tissue. Multiple immunofluorescence assays were performed against different species of Aβ and the main elements that constitute the NVU. Our results showed that there are insoluble vascular deposits of both full-length and truncated Aβ species. Besides, insoluble aggregates are associated with a decrease in the phenotype of the cellular components that constitute the NVU and with BBB disruption. This approach could help identify new therapeutic targets against key molecules and receptors in the NVU that can prevent the accumulation of vascular fibrillar Aβ in AD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. The Neurovascular Unit Dysfunction in Alzheimer's Disease.
- Author
-
Soto-Rojas, Luis O., Pacheco-Herrero, Mar, Martínez-Gómez, Paola A., Campa-Córdoba, B. Berenice, Apátiga-Pérez, Ricardo, Villegas-Rojas, Marcos M., Harrington, Charles R., de la Cruz, Fidel, Garcés-Ramírez, Linda, and Luna-Muñoz, José
- Subjects
- *
ALZHEIMER'S disease , *NEUROFIBRILLARY tangles , *CEREBRAL amyloid angiopathy , *NEURODEGENERATION , *DEMENTIA , *BLOOD vessels - Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disease worldwide. Histopathologically, AD presents with two hallmarks: neurofibrillary tangles (NFTs), and aggregates of amyloid β peptide (Aβ) both in the brain parenchyma as neuritic plaques, and around blood vessels as cerebral amyloid angiopathy (CAA). According to the vascular hypothesis of AD, vascular risk factors can result in dysregulation of the neurovascular unit (NVU) and hypoxia. Hypoxia may reduce Aβ clearance from the brain and increase its production, leading to both parenchymal and vascular accumulation of Aβ. An increase in Aβ amplifies neuronal dysfunction, NFT formation, and accelerates neurodegeneration, resulting in dementia. In recent decades, therapeutic approaches have attempted to decrease the levels of abnormal Aβ or tau levels in the AD brain. However, several of these approaches have either been associated with an inappropriate immune response triggering inflammation, or have failed to improve cognition. Here, we review the pathogenesis and potential therapeutic targets associated with dysfunction of the NVU in AD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Toxicity evaluation of barium ferrite nanoparticles in bacteria, yeast and nematode.
- Author
-
Alvino, Lilibette, Pacheco-Herrero, Mar, López-Lorente, Ángela I., Quiñones, Zahíra, Cárdenas, Soledad, and González-Sánchez, Zaira Isabel
- Subjects
- *
BARIUM ferrite , *NANOPARTICLES , *CAENORHABDITIS elegans , *MAGNETIC recording media , *YEAST , *GRAM-positive bacteria - Abstract
Barium ferrite nanoparticles (BaFeNPs) are a permanent magnetic nanomaterial widely used in electrical energy storage, recording media or in the improvement of the magnetic properties of other nanoparticles (NPs). However, the information about the toxicity of BaFeNPs is almost non-existent. Thus, in the present work, the antimicrobial effect of BaFeNPs was evaluated for the first time in gram-negative and gram-positive bacteria and yeast showing neither antibacterial nor antifungal activity at moderate concentrations. On the other hand, in order to assess the in vivo toxicity of BaFeNPs the model organism Caenorhabditis elegans was used and ingestion, survival, reproduction and ROS production were evaluated in worms treated with different concentrations of BaFeNPs. Our results show that worms ingest these NPs through the digestive system affecting survival, reproduction and ROS production. Image 1 • The diverse uses of BaFeNPs can cause the release of these NPs to the environment. • Information about the toxicity of BaFeNPs is almost non-existent. • Growth of bacteria and yeast treated with NPs was assessed showing no differences. • Survival, reproduction and ROS were evaluated in C. elegans treated with BaFeNPs. • BaFeNPs affect the worm survival, reproduction and ROS production. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. Acceptability and adoption of clinical practice guidelines and treatment protocols on preeclampsia/eclampsia in the Dominican Republic.
- Author
-
De la Rosa, Andelys, Mordan, José, Barinas, Indiana, Toribio, Mayra, Mancebo, Diana, Rodríguez, Alexandra, and Pacheco-Herrero, Mar
- Subjects
- *
MEDICAL personnel , *ECLAMPSIA , *PREECLAMPSIA , *MEDICAL protocols , *MEDICAL care , *WOMEN'S hospitals - Abstract
Objective. Estimate the acceptability and adoption by health care workers of clinical practice guidelines and treatment protocols for women with preeclampsia/eclampsia and identify the facilitating factors and barriers to their implementation. Methods. A qualitative study was conducted, using semi-structured interviews and focus groups in five maternity hospitals. Interviews were compiled for analysis, and barriers and facilitators were characterized. Results. Seventy health professionals (52 female and 18 male) participated, representing different levels of the health system. The majority of workers and managers were aware of the existence and content of clinical practice guidelines (CPGs) for preeclampsia/eclampsia, especially the participants with more time in the health service. With respect to facilitating factors, both medical and nursing staff were positive about continued development and implementation of high-quality CPGs. There was consensus that limitations exist, especially with respect to a lack of the necessary medicines, supplies, and equipment to meet and implement the established recommendations. Discussion. The results of the study show the need to strengthen strategies that help close the gap between research and public policy. Studies suggest that research should focus on users, policymakers, and decisionmakers in the health system. The actors in the Dominican health system recognize the GRADE methodology as an appropriate instrument for the development and implementation of CPGs. Implementation barriers require systemic and comprehensive approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Corrigendum to "Early intervention with ABA prevents neuroinflammation and memory impairment in a triple transgenic mice model of Alzheimer´s disease" [Behav. Brain Res. 374 (2019) 112106].
- Author
-
Espinosa-Fernández, Verónica, Mañas-Ojeda, Aroa, Pacheco-Herrero, Mar, Castro-Salazar, Ernestina, Ros-Bernal, Francisco, and Sánchez-Pérez, Ana María
- Subjects
- *
ALZHEIMER'S disease , *TRANSGENIC mice , *INFLAMMATION , *DISABILITIES - Published
- 2020
- Full Text
- View/download PDF
25. Early intervention with ABA prevents neuroinflammation and memory impairment in a triple transgenic mice model of Alzheimer´s disease.
- Author
-
Espinosa-Fernández, Verónica, Mañas-Ojeda, Aroa, Pacheco-Herrero, Mar, Castro-Salazar, Ernestina, Ros-Bernal, Francisco, and Sánchez-Pérez, Ana María
- Subjects
- *
ALZHEIMER'S disease , *TRANSGENIC mice , *CENTRAL nervous system , *ABSCISIC acid , *MEMORY , *NATURAL numbers - Abstract
• Abscisic Acid (ABA) treatment can effectively prevent memory impairment in a murine model of Alzheimer disease (AD). • ABA treatment can prevent microglia transition to inflammatory state in transgenic model of AD. • The beneficial effects of ABA, PPARᵧ agonist and an insulin sensitizer in the central nervous system are independent of peripheral insulin resistance. • Further studies will establish whether later intervention (when the disease may be in initial stages), but longer treatments can guarantee better rescue of memory impairment. Neuroinflammation and insulin resistance in the brain are intimately linked to neurodegenerative disorders, including Alzheimer's disease. Even though traditionally Alzheimer´s disease has been associated to Aβ deposits and hyperphosphorylated Tau intracellular tangles, several studies show that neuroinflammation may be the initial cause that triggers degeneration. Accordingly, a number of natural supplements that improves brain insulin sensitivity and reduce neuroinflammation have been proposed as good choices in the therapeutic prevention of cognitive decline. Further supporting this evidence, we show that phytohormone Abscisic Acid, can prevent memory impairment and neuroinflammation markers in a triple transgenic mouse model, where no peripheral inflammatory changes have occurred. Moreover, our data strongly suggests that early intervention is critical for good prognosis, and that cognitive improvement requires longer treatment than recovering neuroinflammation markers. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.